bravo1954/E+ via Getty Images A post-hoc analysis found that AbbVie’s (NYSE:ABBV) Rinvoq (upadacitinib) was found
Enes Evren/E+ via Getty Images AbbVie (NYSE:ABBV) subsidiary Allergan Cosmetics has launched Botox (onabotulinumtoxinA) in
AbbVie (NYSE:ABBV) declared $1.55/share quarterly dividend, in line with previous. Forward yield 3.19% Payable Nov. 15;
Summary: AbbVie’s stock has risen to an all-time high, raising the question of whether it’s
Summary: AbbVie delivered Y/Y growth in the second quarter despite Humira’s decline, with Skyrizi and
Summary: AbbVie’s turnaround is in full force, driven by solid performances from Skyrizi and Rinvoq,
Summary: AbbVie shares are nearing $200, likely facing resistance and a potential pullback to test
Eoneren Update: Adds additional information Neurocrine Biosciences (NASDAQ:NBIX) said on Wednesday its experimental oral drug
Summary: AbbVie is one of my biggest winners and a top 10 holding in my
Summary: AbbVie has shown strong growth, especially in immunology and oncology, with Skyrizi and Rinvoq